



# **Electronic Publication of Patents Journal under The Patents (Amendments) Act, 2016**

Weekending:- 18-05-2018

Legal Publication Date:- 13-06-2018

Journal Code (180613)



**NEW APPLICATIONS FOR THE PATENTS**

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

<b>14-05-2018</b>		
346/2018	Dr. Muhammad Athar Abbasi Dr. Khalid Mohammad Khan Dr. Aziuz-ur-Rehman Dr. Shahnaz Perveen Dr. Sabahat Zahar Siddiqui Dr. Muhammad Ashraf <b>PCSIR</b> Pakistan	“A process for the preparation of fluorinated sulfonamide as potent anti-diabetic agent: N-(4-ethylphenyl)-N-(4-fluorobenzyl)-2,3-dihydro-1,4-benzodioxine-6-sulfonamide”
347/2018	Dr. Gul-e-Rana <b>PCSIR</b> Karachi – Pakistan	“Development of Method for preparation of Charcoal Face Mask from Pakistani Lignite Coal Char”
348/2018	COMSATS UNIVERSITY Islamabad – Pakistan	“A surveillance system with enhanced Sound Receiving Method integrated with Video Surveillance Equipment”
<b>15-05-2018</b>		
349/2018	Anglo American Services (UK) Ltd. United Kingdom (Priority 23-06-2017 US)	“Beneficiation of Values from Ores with a Heap Leach Process”
350/2018	Yuan-Cheng CHIEN Taiwan	“Deformable Tampon”
<b>16-05-2018</b>		
351/2018	CCL Secure Pty Ltd,	“A BANKNOTE, A METHOD OF

	Australia (Priority 17-05-2017 Australia)	PRODUCING A BANKNOTE, A COATING FOR A BANKNOTE AND A SECURITY FEATHRE FOR A BANKNOT”
<b>17-05-2018</b>		
352/2018	Reckitt Benckiser LLC, USA (Priority 17-05-2017 GB)	“COMPOSITION”
353/2018	Novartis AG Switzerland (Priority 19-05-2017 US)	“COMPOUNDS AND COMPOSITIONS FOR TREATING SOLID TUMORS BY INTRATUMORAL ADMINISTRATION”
<b>18-05-2018</b>		
354/2018	Select Sport A/S Denmark (Priority 19-05-2017 DK)	“SPORTS BALL’S CASING AND METHODS OF MANUFACTURING A SPORTS BALL’S CASING USING ULTRASONIC WELDING”
355/2018	Mr. Usama Bin Shakeel Mr. Syed Ali Jaffer Mr. Fahim Ali Dr. Sajjad Zaidi <b>NUST</b> Islamabad – Pakistan	“Three Phase Load Balancer”
356/2018	Qarshi Industries (Pvt) Ltd. KPK – Pakistan	“LICORICE CONTAINING CAFFEIN AND PHOSPHORIC ACID FREE NATURAL BEVERAGE COMPOSITION”

**APPLICATION ACCEPTED**

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Patents' journal may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.


The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

371/2007	ENI S.P.A., Italy.	<p>"PROCESS FOR THE PRODUCTION OF STABLE AQUEOUS SUSPENSIONS OF SULPHUR STARTING FROM HYDROGEN SULPHIDE AND POSSIBLE DISPOSAL OF THE SUSPENSIONS THUS OBTAINED"</p> <p>C01B17/05 &amp; B01D53/52.</p> <p style="text-align: right;"><b>142814</b></p> <p>Process for the production of stable sulphur suspensions starting from hydrogen sulphide contained in fossil fuels comprising:</p> <p>a. oxidizing an aliquot of hydrogen sulphide to sulphur dioxide;</p> <p>b. dissolving the sulphur dioxide thus produced in brackish water or sea water;</p> <p>C. effecting the reaction (I) :</p> $2H_2S + SO_2 \rightarrow 3S + 2H_2O \quad (I)$ <p>by putting the remaining hydrogen sulphide in contact with the solution prepared in step (b); and</p> <p>d. removing the suspension thus obtained.</p>
----------	-----------------------	---


<p>1411/ 2007</p>	<p>Janssen Pharmaceutica N.V., Belgium</p>	<p>"A novel substituted quinoline compound"</p> <p>C07D215/14, C07D401/04, C07D413/04, C07D417/04, A61K31/496 &amp; A61P31/04.</p> <p style="text-align: right;"><b>142815</b></p> <p>The present invention relates to novel substituted quinoline compound according to the general formula (Ia) or formula (Ib):</p> <div style="text-align: center;"> <p>(Ia)</p> <p>(Ib)</p> </div> <p>The claimed compound are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compound, the use of the claimed compound or composition for the manufacture of a medicament for the treatment of a bacterial infection and a process for preparing the claimed compound.</p>
<p>1413/ 2007</p>	<p>Janssen Pharmaceutica N.V., Belgium</p>	<p>"A novel substituted quinoline compound"</p> <p>C07D215/22, C07D401/06, C07D409/10, A61K31/435 &amp; A61P31/00.</p> <p style="text-align: right;"><b>142816</b></p> <p>The present invention relates to novel substituted quinoline compound according to the general Formula (Ia) or Formula (Ib):</p>


		 <p>(1a)</p> <p>(1b)</p> <p>The claimed compound is useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compound, the use of the claimed compound or composition for the manufacture of a medicament for the treatment of a bacterial infection and a process for preparing the claimed compound.</p>
<p>198/2009</p>	<p>Ardea Biosciences, Inc., U.S.A.</p>	<p>“DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME”</p> <p>A01N41/06.</p> <p style="text-align: right;"><b>142817</b></p> <p>This invention concerns N-(2-arylamino) aryl sulfonamide compounds which are inhibitors of MEK including crystalline polymorphic forms which exhibit a specific powder x-ray diffraction profile and/or a specific differential scanning calorimetry profile. This invention also concerns pharmaceutical compositions comprising A compound disclosed herein and methods of use of the compounds and compositions described herein, including the use in the treatment and/or prevention of cancer, hyperproliferative disorders and inflammatory conditions. The invention also</p>



		<p>concerns methods of making the compounds and compositions described herein.</p>
<p>404/ 2010</p>	<p>Ceravision Limited, Great Britain.</p>	<p>“ A LIGHT SOURCE FOR A MICROWAVE-POWERED LAMP”</p> <p>H01J65/04.</p> <p style="text-align: right;"><b>142818</b></p> <p>A lamp (1) comprises an oscillator and amplifier source (2) of microwave energy, typically operating at 2.45 or 5.8 GHz or other frequencies within an ISM band. The source passes the microwaves via a matching circuit (3) to an antenna (4) extending into a re-entrant (5) in a lucent waveguide (6). This is of quartz and has a central cavity (7) accommodating a bulb (8.) The bulb is a sealed tube (9) of quartz and contains a fill of noble gas and a microwave excitable material, which radiates visible light when excited by microwaves. The bulb has a stem (10) received in a stem bore (11) extending from the central cavity. The waveguide is transparent and light from the bulb can leave it in any direction, subject to any reflective surfaces. Microwaves cannot leave the waveguide, which is limited at its surfaces by a Faraday cage. Typically this comprises an ITO coating (12) on a front face of the waveguide, a light reflective coating (10), typically of silver with silicon monoxide coating (13) on a rear face and a wire mesh (14), which contacts both the ITO and light reflective coatings and is grounded, the wire mesh extending around sides of the waveguide between the front and back surfaces. Light can pass through the wire mesh for collection and use.</p>

<p>422/ 2010</p>	<p>Merck Sharp &amp; Dohme Corp. U.S.A.</p>	<p>“ARYL METHYL BENZOQUINAZOLINONE MI RECEPTOR POSITIVE ALLOSTERIC MODULATOR”</p> <p>C07D239/88, C07D401/06, C07D401/14, C07D403/04, C07D471/04, A61K31/517 &amp; A61P25/28.</p> <p style="text-align: right;"><b>142819</b></p> <p>The present invention is directed to a benzoquinazolinone compound of formula (I)</p> <div style="text-align: center;"> </div> <p>which is MI receptor positive allosteric modulator and that is useful in the treatment of diseases in which the MI receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to a pharmaceutical composition comprising the compound, for use in the treatment of diseases mediated by the MI receptor.</p>
<p>445/ 2011</p>	<p>Ardea Biosciences, Inc., U.S.A.</p>	<p>“Thioacetate compound and composition”</p>




		<p>C07D213/70, C07D401/04, C07D241/18, A61K31/44, A61K31/444, A61K31/4965, A61P19/06 &amp; A61P9/12.</p> <p style="text-align: right;"><b>142820</b></p> <p>Described herein is a compound of formula</p> <div style="text-align: center;">  </div> <p>useful in the modulation of blood uric acid levels and a composition containing it. In some embodiments, the compound described herein is used in the treatment or prevention of disorders related to aberrant levels of uric acid.</p>
<p>324/2012</p>	<p>SICPA HOLDING SA, Switzerland</p>	<p>“POLYMER-BONDED QUATERRYLENE AND/OR TERRYLENE DYE AND COMPOSITION CONTAINING SAME”</p> <p>C09B3/20, C09D11/00 &amp; C09B69/10.</p> <p style="text-align: right;"><b>142821</b></p> <p>The invention provides a method of increasing the solubility and/or dispersibility of a quaterrylene and/or terrylene dye in a liquid medium such as, e.g., a liquid medium comprised in a printing ink composition. The method comprises binding the quaterrylene and/or terrylene dye to a polymer which is soluble in the liquid medium.</p> <p>The invention also provides a printing ink composition which comprises a polar liquid medium that has at least one polymer-bonded quaterrylene and/or terrylene dye of the present invention as set forth above (including the various aspects thereof) dissolved or dispersed therein.</p>


<p>330/ 2012</p>	<p>Glaxo Group Limited United Kingdom.</p>	<p>“ B Cell Maturation Antigen (BCMA) binding protein”</p> <p>C07K16/28 &amp; A61K47/48.</p> <p style="text-align: right;"><b>142822</b></p> <p>The invention relates to antigen binding protein and fragment thereof and provides an antigen binding protein which specifically binds B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and/or APRIL to BCMA receptor. The invention further provides an immunoconjugate and pharmaceutical composition comprising the antigen binding protein for use in the treatment of B cell lymphoma such as Multiple Myeloma (MM) or chronic Lymphocytic Leukaemia (CLL).</p>
<p>894/ 2012</p>	<p>GENENTECH, INC., U.S.A</p>	<p>“ INHIBITOR OF IAP”</p> <p>C07D417/14.</p> <p style="text-align: right;"><b>142823</b></p> <p>Novel inhibitor of IAP that is useful as therapeutic agent for treating malignancies and has the general formula I:</p> <div style="text-align: center;">  <p>(I)</p> </div> <p>wherein Ph is phenyl; R<sup>1</sup> is C<sub>3-7</sub> cycloalkyl; R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> are each independently in each occurrence H or C<sub>1-6</sub> alkyl.</p>
<p>47/ 2013</p>	<p>Novartis AG. Switzerland.</p>	<p>“ IMIDAZOPYRROLIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION</p>


		<p>THEREOF”</p> <p>C07D487/04, A61K31/4188 &amp; A61P35/00.</p> <p style="text-align: right;"><b>142824</b></p> <p>The invention relates to compound of formula (I):</p>  <p>as described herein, pharmaceutical preparations comprising such compound, uses and methods of use for such compound in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compound.</p>
<p>59/ 2013</p>	<p>Merck Sharp &amp; Dohme Corp. U.S.A.</p>	<p>“PHARMACEUTICALLY ACCEPTABLE SALT OF ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR”</p> <p style="text-align: right;"><b>142825</b></p> <p>The present invention is directed to a pharmaceutically acceptable salt of a benzoquinazolinone compound of formula (I)</p> 

		<p>which is M1 receptor positive allosteric modulator and that is useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to a pharmaceutical composition comprising the said pharmaceutically acceptable salt of the compound of formula (I), for use in the treatment of diseases mediated by the M1 receptor.</p>
<p>254/ 2013</p>	<p>NIHA CORPORATION, USA.</p>	<p>“PROCESS OF PRODUCING BIO-ORGANO-PHOSPHATE (BOP) FERTILIZER THROUGH CONTINUOUS SOLUBILIZATION OF ROCK PHOSPHATE BY A COMPOSTING BIOPROCESS AND BIOAUGMENTATION WITH PHOSPHORUS SOLUBILIZING MICROORGANISMS”</p> <p>C05B15/00.</p> <p style="text-align: right;"><b>142826</b></p> <p>A method and processes to solubilize and transform phosphorus contents of rock phosphate (RP) into bio-organo-phosphate (BOP) fertilizer have been developed and integrated. The methods include collecting and sorting of organic wastes; blending with RP; subjected the blend to biocoosting; collection, isolation, selection and growth optimization of consortia of efficient phosphorus solubilizing microorganisms (PSM) and novel plant growth regulating microorganisms (PGRM); where in PSM produce organic acids and other organic compounds using compost substrate at mesophilic stage, whereas the organic acids released during composting also act in synergism of PSM, thus forming a carbon rich acidic culture resulting in the solubilization of rock phosphate. Exposure of rock phosphate to organic acid rich culture and augmentation with PSM results into solubilization of phosphorus and conversion into</p>

		<p>organic phosphorus containing the product: BOP fertilizer. The bioavailability of P may be further enhanced through bioaugmentation of BOP with novel PGRM that improves the root architecture for better uptake of phosphorous.</p>
<p>452/2014</p>	<p>SANTONI S.P.A. Italy.</p>	<p>“Device for Feeding Thread to Needles of a Knitting Machine”</p> <p>D04B15/60.</p> <p style="text-align: right;"><b>142827</b></p> <p>A device (1) for feeding thread to needles (N) of a knitting machine, the device comprising a body destined to be associated to a knitting machine at a needle-bearing organ of the knitting machine, and provided with at least a housing seating configured such as to movably house thread guide means (4) in the body (2). The device is provided with thread guide means (4), movably housed at least partially in the at least a housing seating and comprising at least a thread guide (6) having an elongate conformation and extending longitudinally between a rear end (7) and a front end (8); the front end projecting and emerging from the seating (3) in a direction of the needle-bearing organ and defining at least a passage ( for a thread to be dispensed to the needles (N) of the needle-bearing organ. The thread guide means further comprise activating means (13) positioned at least partially in the seating and configured and predisposed to controllably move the thread guide (6) 50 as to position the thread guide (6) in a plurality of operating positions with respect to the seating and with respect to the needle-bearing organ of the knitting machine. The seating is further profiled so as to guide the movement of the thread guide means (4), in particular so as to guide the movement of the thread guide means (6) in the movement thereof between the plurality of operating positions, and/or so as to guarantee maintenance of each operating position assumed by the thread guide during the working of the knitting machine.</p>

		
<p>174/2015</p>	<p>Arr-Maz Products, L.P. U.S.A.</p>	<p>“ATTRITION RESISTANT PROPPANT COMPOSITE AND ITS COMPOSITION MATTERS”</p> <p>C09K8/80, E21B43/26 &amp; E21B43/247.</p> <p style="text-align: right;"><b>142828</b></p> <p>A hydraulic fracturing and gravel packing proppant composite with protectant on the surface of the proppant and the composition matters of the protectant and proppant. The surface protectant reduces the generation of dust/fines from the proppant caused by abrasion and impingement during transportation and conveyance, particularly pneumatic transfer.</p>
<p>550/2015</p>	<p>NIHA CORPORATION, Canada.</p>	<p>“BIOACTIVE NUTRIENT FORTIFIED FERTILIZERS”</p> <p>C05F11/08, C05G3/00 &amp; C05B15/00.</p> <p style="text-align: right;"><b>142829</b></p> <p>The invention relates to Bioactive Nutrient Fortified Fertilizer (BNFF) for making new generation fertilizer. A BNFF fertilizer comprises on fertilizer particle, a layer of Bio-activated Immobile/Less Mobile Macro/Micro plant Food Nutrient rich in a target nutrient element like P, Zn,</p>

		<p>Fe, S, etc., Element Mobilizing Microorganisms (EMM), organic matter and layer of outer coating of bioactive coating comprising of target nutrient mobilizing microbes and other essential ingredients. Bioactive nutrient is placed in between fertilizer particle and bio-active coating.</p> <p>Bio-activation process mobilize immobile/less immobile nutrients elements to plants by action of EMM, which are isolated, cultured, and combined with organic material and sources of the immobile /less immobile element.</p> <p>The Bioactive Nutrient has higher bioavailability and less prone to fixation or leaching losses ensuring availability to crop plants for longer period of times. An ample supply of the Bioactive Nutrient eliminates deficiency of the target nutrient element and improve efficiency of other applied/available nutrients leading to better crop yield and agricultural productivity.</p>
<p>766/ 2015</p>	<p>AstraZeneca AB Sweden.</p>	<p>“1-[2-(AMINOMETHYL)BENZYL]-2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITOR OF MYELOPEROXIDASE”</p> <p>C07D487/04, A61K31/519 &amp; A61P9/10.</p> <p style="text-align: right;"><b>142830</b></p> <p>There are disclosed 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin- 4-one compound of formula (I),</p> <div style="text-align: center;">  <p>(I)</p> </div>

		<p>wherein  R1 is H, F, Cl or CF3;  R2 is H, CH3 or C2H5; and  R3 is H, CH3, C2H5, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl or cyclopentyl;  with a composition—containing it. The compound is an inhibitor of the enzyme mpo and is thereby particularly useful in the treatment or prophylaxis of cardiovascular disorders such as heart failure and coronary artery disease related conditions.</p>
800/ 2015	ELI LILLY AND COMPANY U.S.A.	<p>“6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amjno]pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl] -5,6-dihydro-4H-thieno [2,3-c] pyrrol-4-one compound and pharmaceutical composition thereof”</p> <p>C07D513/04 &amp; A61K31/506.</p> <p style="text-align: right;"><b>142831</b></p> <p>The present invention relates to a compound of the formula:</p>  <p>Wherein R<sup>1</sup> to R<sup>5</sup> are as defined in the claims of the specification.  The present invention further provides a pharmaceutical composition comprising the claimed compound and a pharmaceutically acceptable carrier, diluent, or excipient. The compound of the present invention inhibits the activity of extracellular-signal-regulated kinase (ERK) and effective to treat cancer.</p>
264/ 2016	Kikuo YAMADA Japan.	<p>“Base fabric for disposable textile product and disposable textile product using same”</p>





B32B7/14 & B32B5/26.

142832

The present invention provides a base fabric for a disposable textile product that excels in moisture transpiration ability, heat dissipation ability, and moisture permeability. The invention also provides the disposable textile product that uses the base fabric for the disposable textile product, which excels in feeling in wearing and contact with the skin and also excels in moisture transpiration ability, heat dissipation ability, and moisture permeability.

The base fabric for the disposable textile product is configured of a laminated sheet 30 which has a first fibrous sheet 2 and a second fibrous sheet 3 having air permeability and a fiber material 4 interposed between the first fibrous sheet 2 and the second fibrous sheet 3 and having liquid diffusibility, and in which the first fibrous sheet 2 and the second fibrous sheet 3 and the fiber material 4 are laminated together with an elastic member 5. The laminated sheet 30 forms a composite layer 31 in which a fiber layer having the air permeability and a fiber layer having the liquid diffusibility are laminated. The laminated sheet 30 has a shirring portion 6 in which an uneven surface is formed by the composite layer 31. Elasticity is imparted to the laminated sheet 30.



177/2017	ELI LILLY AND COMPANY. U.S.A.	<p>“ pharmaceutically acceptable salt of 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino] pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one compound and pharmaceutical composition thereof”</p> <p>C07D513/04 &amp; A61K31/506.</p> <p style="text-align: right;"><b>142833</b></p> <p>The present invention relates to a pharmaceutically acceptable salt of a compound of the formula:</p> <div style="text-align: center;">  </div> <p>Wherein R<sup>1</sup> to R<sup>5</sup> are as defined in the claims of the specification.</p> <p>The present invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound and a pharmaceutically acceptable carrier, diluent, or excipient. The pharmaceutically acceptable salt of a compound of the present invention inhibits the activity of extracellular-signal-regulated kinase (ERK) and effective to treat cancer.</p>
----------	----------------------------------	---

**CORRIGENDUM**

In the Patent's journal issued dated **30-05-2018**, under the heading "**NEW APPLICATIONS FOR THE PATENTS**". The following correction are as under :-

**(Week Ending 04-05-2018)**

**NEW APPLICATIONS FOR THE PATENTS**  
**(Change in Applicant Name with Country and Title against Application No.301/2018 only)**

For : Existing entry.

Read : BAYER CROPSCIENCE AKTIENGESELLSCHAFT  
Germany  
(Priority 04-05-2017 EP)  
"NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES".

**SEALING FEES DUE-**

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.4500/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

<b>Accepted No.</b>	<b>Applicant Name</b>	<b>Application No.</b>
142662	BOEHRINGER INGELHEIM INTERNATIONAL GmbH, Germany.	808/2004
142663	UNILEVER PLC, United Kingdom	1108/2006
142664	ESCO CORPORATION USA	153/2007
142665	SYNGENTA PARTICIPATIONS AG Switzerland SYNGENTA LIMITED United Kingdom	497/2009
142666	Endotronix Inc., USA	189/2011
142667	Industrie De Nora S.p.A., Italy.	271/2012
142668	DOLBY LABORATORIES LICENSING CORPORATION USA	650/2012
142669	BSW Machinery Handels-GmbH, Austria	230/2013
142670	CJ CHEILJEDANG CORPORATION Republic of Korea.	119/2014
142671	UPL LIMITED India	320/2014
142672	SOCIEDAD ESPANOLA DEELECTROMEDICINA Y CALIDAD, S.A. SPAIN	458/2014
142673	ELI LILLY AND COMPANY USA	857/2014

142674	UNILEVER PLC, United Kingdom	864/2014
142675	Novartis AG Switzerland	154/2015
142676	PFIZER INC. USA	493/2015
142677	CHIESI FARMACEUTICI S.P.A., Italy.	302/2016
142678	BOEHRINGER INGELHEIM INTERNATIONAL GmbH, Germany.	572/2016
142679	PFIZER INC. USA	278/2017
142680	Council of Scientific & Industrial Research India	276/2003
142681	Takeda GmbH Germany	762/2004
142682	Core Wireless Licensing S.a.r.l.,, Luxembourg	925/2005
142683	MASCHINENFABRIK RIETER AG Switzerland	812/2006
142684	Core Wireless Licensing S.a.r.l.,, Luxembourg	226/2013
142685	EXEGER SWEDEN AB Sweden	649/2014

**NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS**

<b>S. No.</b>	<b>Design No.</b>	<b>Title &amp; Class</b>	<b>Applicant</b>
<b>14/05/2018</b>			
<b>1.</b>	<b>19323</b>	<b>Football (Class No-06)</b>	<b>Mr. Ali Hasnain Hussain</b>
<b>16/05/2018</b>			
<b>2.</b>	<b>19324</b>	<b>Shoe (Class-10)</b>	<b>XARASOFT Pvt. Ltd.</b>
<b>3.</b>	<b>19325</b>	<b>Shoe (Class-10)</b>	<b>XARASOFT Pvt. Ltd.</b>
<b>4.</b>	<b>19326</b>	<b>Chappel (Class-10)</b>	<b>XARASOFT Pvt. Ltd.</b>
<b>5.</b>	<b>19327</b>	<b>Shoe (Class-10)</b>	<b>XARASOFT Pvt. Ltd.,</b>
<b>6.</b>	<b>19328</b>	<b>Chappel (Class-10)</b>	<b>XARASOFT Pvt. Ltd.</b>
<b>7.</b>	<b>19329</b>	<b>Cistern Flash Tank (Class-03)</b>	<b>Abdul Sattar</b>
<b>8.</b>	<b>19330</b>	<b>Commode Seat Cover (Class-03)</b>	<b>Abdul Sattar</b>
<b>17/05/2018</b>			
<b>9.</b>	<b>19331</b>	<b>Solid Fuel Stove</b>	<b>Lt Col. (R) Mahmud Shah</b>
<b>18/05/2018</b>			
<b>10.</b>	<b>19332</b>	<b>PACKAGING (Class-03)</b>	<b>Ecolean AB</b>
<b>11.</b>	<b>19333</b>	<b>PACKAGING (Class-03)</b>	<b>Ecolean AB,</b>
<b>12.</b>	<b>19334</b>	<b>PACKAGING (Class-03)</b>	<b>Ecolean AB,</b>
<b>13.</b>	<b>19335</b>	<b>PACKAGING (Class-03)</b>	<b>Ecolean AB,</b>
<b>14.</b>	<b>19336</b>	<b>PACKAGING (Class-03)</b>	<b>Ecolean AB,</b>
<b>15.</b>	<b>19337</b>	<b>PACKAGING (Class-03)</b>	<b>Ecolean AB,</b>
<b>16.</b>	<b>19338</b>	<b>PACKAGING (Class-03)</b>	<b>Ecolean AB,</b>
<b>17.</b>	<b>19339</b>	<b>PACKAGING (Class-03)</b>	<b>Ecolean AB,</b>

**REGISTRATION OF DESIGNS**

The following designs have been registered.

S. No.	Design No.	Title & Class	Applicant
<b><u>03/05/2018</u></b>			
1.	17734	Bottle (Class-03)	Auvitronics Limited
<b><u>17/05/2018</u></b>			
2.	18815	Container (Class-03)	Total SA
3.	18816	Container (Class-03)	Total SA
4.	19097	Chocolate Car (Class-12)	Pervaiz Pyar Ali
5.	19098	Chocolate Mobile (Class-12)	Pervaiz Pyar Ali
6.	18626	Plastic Marker (Class-03)	Mark Industries
7.	18695	Plastic Bottle (Class-03)	Well Zaitun International Cosmetics
8.	17826	The Body of Mattress Cover (Class-14)	Zam Zam Emporium
9.	19067	Plate (Class-03)	Dove Melamine Ware
10.	19068	Bowl (Class-03)	Dove Melamine Ware
11.	19102	Fineliner Pen (Class-03)	Sayyed Engineers Limited
12.	18673	Jug (Class-03)	Shoaibee Industries
13.	18674	Cup (Class-03)	Shoaibee Industries
14.	18597	Bottle (Class-03)	Mehran Spice & Food Industries
15.	18398	Fuel Dispenser Shade (Class-01)	Horizon Oil Company (Private) Limited
16.	18831	Piano Highlighter (Class-03)	Sayyed Engineers Limited
17.	18832	Piano Smooth Gel pen (Class-03)	Sayyed Engineers Limited
18.	18661	A Bat (Class-03)	Passive Power Pty Ltd,
19.	17787	Mobile Phone (Class-03)	Digicom Trading (Pvt) Limited
20.	17788	Mobile Phone (Class-03)	Digicom Trading (Pvt) Limited
21.	19066	Rooftop AC Shroud/Console (Class-03)	Thal Limited
22.	18376	Serving Dish With Lid (Class-03)	Dove Melamine Ware
23.	18545	Soap Bar (Class-12)	Unilever PLC

24.	18684	Parodontax (Class-05)	Stafford-Miller (Ireland) Limited
25.	18685	Parodontax (Class-05)	Stafford-Miller (Ireland) Limited
26.	18686	Parodontax (Class-05)	Stafford-Miller (Ireland) Limited
27.	18687	Parodontax (Class-05)	Stafford-Miller (Ireland) Limited
28.	19092	Tweezer with Comb (Class-01)	Zona Industries
29.	19093	Eyebrow Divider (Class-01)	Zona Industries
30.	19094	Tweezers (Class-01)	Zona Industries
31.	19127	SHARPENER (Class-03)	National Cottage Industries
32.	19128	SHARPENER (Class-03)	National Cottage Industries
33.	19125	SHARPENER (Class-03)	National Cottage Industries
34.	19029	Sports ball (Class-06)	Kicker Sports
<b><u>18/05/2018</u></b>			
35.	19089	IOT Connected Ovitrap with Real Time Mosquito Count (Class-03)	Salman Atif and Muhammad Ali Tahir
36.	19090	1 DoF (Degree of Freedom) upper limb Prosthetic gripper (Class-03)	Muhammad Saad bin Ubaid
37.	19091	6 DoF (Degree of Freedom) upper limb Prosthetic gripper (Class-03)	Mustafa Arsal Shahid



**(Dr. Muhammad Fayyaz Ahmad)**  
 Controller of Patents  
 & Registrar of Designs  
**Ph: 99230591**